Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 03, 2023

BUY
$14.15 - $22.03 $147,683 - $229,927
10,437 New
10,437 $198 Million

Others Institutions Holding ETNB

About 89bio, Inc.


  • Ticker ETNB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,484,500
  • Market Cap $422M
  • Description
  • 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...
More about ETNB
Track This Portfolio

Track Innovis Asset Management LLC Portfolio

Follow Innovis Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Innovis Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Innovis Asset Management LLC with notifications on news.